Objective: Reducing time to reperfusion for ST-segment elevation myocardial infarction (STEMI) is essential in improving outcomes. Consequently, numerous strategies have been employed to reduce median door-to-balloon time (DTBT).

Methods: CODE STEMI is an ED physician-activated STEMI notification system. On activation, an announcement is made over the hospital's public announcement (PA) system. We prospectively analysed all in-hours STEMI patients who had primary percutaneous coronary intervention (PPCI) Pre-CODE STEMI (2014) and after CODE STEMI was implemented (2015). The primary end-points were median DTBT and the proportion of STEMI patients achieving a DTBT ≤90 min. The secondary end-points were in-hospital outcomes, and a composite of major adverse cardiac events (MACE) and hospital readmission rates at 30 days and 12 months.

Results: There were 41 and 42 patients in Pre-CODE STEMI and CODE STEMI groups respectively. Baseline characteristics were similar. DTBT was significantly reduced by 22.1 min from 67.1 ± 34.9 min Pre-CODE STEMI to 45.0 ± 22.7 min (P = 0.001) in the CODE STEMI group. Door-to-door time (DTDT) was also reduced from 46.3 ± 30.9 min to 29.4 ± 23.3 min (P = 0.006). A greater proportion of CODE STEMI patients achieved the target DTBT ≤90 min (95.2% vs 73.2%, P = 0.007). CODE STEMI patients had less systolic dysfunction measured by a left ventricle ejection fraction of ≤40% (10.0% vs 27.8%, P = 0.07). There were trends to lower in-hospital mortality rates (4.8% vs 9.8%, P = 0.43), MACE at 30 days and 12 months (4.8% vs 9.8%, P = 0.43; 11.9% vs 22.0%, P = 0.25).

Conclusion: The novel in-hospital in-hours CODE STEMI notification system significantly reduced DTBT in patients undergoing PPCI.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1742-6723.12855DOI Listing

Publication Analysis

Top Keywords

code stemi
28
stemi patients
16
stemi
14
pre-code stemi
12
door-to-balloon time
8
patients undergoing
8
primary percutaneous
8
percutaneous coronary
8
coronary intervention
8
stemi notification
8

Similar Publications

Morphine and P2Y12 Inhibitors in ST-Elevation Myocardial Infarction: An Updated Meta-Analysis.

Am J Cardiovasc Drugs

December 2024

Cardiovascular Institute, Detroit Medical Center, Heart Hospital, Wayne State University, 311 Mack Ave, Detroit, MI, 48201, USA.

Background: Morphine is used to control pain in ST-elevation myocardial infarction but reduces P2Y12 inhibition. It is not known if this modulation of platelet inhibition appreciably affects clinical outcomes.

Methods: We screened 979 articles and identified seven studies that met the eligibility criteria for meta-analysis.

View Article and Find Full Text PDF
Article Synopsis
  • Ticagrelor can be effectively given through a nasogastric tube for patients with acute coronary syndrome (ACS) when they can't take it orally, and it was tested for its effects on platelet inhibition in resuscitated patients and those needing semi-urgent CABG surgery.
  • In the study, crushed ticagrelor tablets resulted in significant platelet inhibition, with 89% of resuscitated patients and 85% of CABG patients showing effective results at 24 hours.
  • The pharmacokinetics revealed a median time to peak plasma concentration of 100 hours for ticagrelor across both patient groups, indicating that crushed administration maintains its effectiveness and absorption metrics similar to previous research.
View Article and Find Full Text PDF

Background: Prior analyses of the relationship between insurance status and receipt of tests and procedures have yielded conflicting findings and have focused on outpatient care. We sought to characterize the relationship between primary payer and diagnostic and procedural intensity, comparing rates of cardiac tests and procedures in matched hospitalized Medicaid and commercially insured patients.

Methods And Results: We created a propensity score-matched sample of Medicaid and commercially insured adults hospitalized at all acute care hospitals in Kentucky, Maryland, New Jersey, and North Carolina from 2016 to 2018.

View Article and Find Full Text PDF
Article Synopsis
  • The article presents the first national guidelines for managing acute coronary syndrome (ACS) in Iran, detailing diagnosis, treatment, and secondary prevention strategies.
  • A group of specialists examined clinical concerns and formulated 13 key questions, leading to recommendations based on systematic evidence review.
  • The guidelines include initial response protocols for chest pain, risk categorization for patients, treatment options in hospitals, and strategies for secondary prevention post-ACS.
View Article and Find Full Text PDF

Circular (circ) RNAs are non-coding RNAs with important functions in the nervous system, cardiovascular system, and cancer. Their role in atherosclerosis and myocardial infarction (MI) remains poorly described. We aim to investigate the potential circRNAs in immune cells during atherogenesis and examine the most regulated during MI and the modulation by interleukin (IL)-6 receptor inhibition by tocilizumab.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!